SequelSEC

TuHURA Biosciences, Inc./NV HURA

Pharmaceutical Preparations · CIK 0001498382 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-03-31
Operating income
Unavailable
Fiscal year ended 2026-03-31
Free cash flow
-$27.39M
Fiscal year ended 2026-03-31

Valuation, from the filing

Public float$111.00MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.74Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity5.3×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio0.78x13th

TuHURA Biosciences, Inc./NV (HURA) reported revenue of $0 and net income of -$30.92M for the fiscal year ended 2026-03-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from TuHURA Biosciences, Inc./NV’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

TuHURA Biosciences, Inc./NV income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-31
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating incomeUnavailable
Net income-$30.92M
Research & development$21.18M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$4.36M
Selling & marketingUnavailable

Balance

TuHURA Biosciences, Inc./NV balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-31
Cash & equivalents$6.30M
Total assets$29.70M
Current assets$6.98M
Total liabilities$6.51M
Current liabilities$6.07M
Total equity incl. NCI$23.19M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
Goodwill$10.74M
Long-term debtUnavailable
Accounts payable$3.95M

Cash flow

TuHURA Biosciences, Inc./NV cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-31
Operating cash flow-$27.30M
Capital expenditures$82.26K
Investing cash flow-$233.16K
Financing cash flow$27.62M
Net change in cash$78.30K
Stock-based compensation$7.80M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$80.68K

Derived

TuHURA Biosciences, Inc./NV derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-31
Free cash flow-$27.39M
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio1.15x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HURA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.